Table 4.

Refinement of the DRI

Disease	Stage	No. of patients	HR*	Original DRI	Percentage of patients	New DRI Group	2-y OS (%)	95% CI
Hodgkin lymphoma CR		126	0.36	Int	14	Low	66	63-68
CLL CR		81	0.47	Low		Low
Mantle cell lymphoma CR		160	0.51	Int		Low
Indolent NHL CR		183	0.53	Low		Low
AML favorable cytogenetics CR		190	0.64	Low		Low
Indolent NHL PR		276	0.71	Low		Low
CLL PR		400	0.78	Low		Low
CML chronic phase 1/2		390	0.82	Low		Low
CML advanced phase		69	0.92	Int	63	Int	51	50-52
Mantle cell lymphoma PR		149	0.95	Int		Int
Myeloproliferative neoplasm	Any	426	0.98	Int		Int
AML intermediate cytogenetics CR		3611	Ref	Int		Int
ALL CR1		1023	1.00	Int		Int
T-cell NHL CR		171	1.00	Int		Int
Multiple myeloma CR/VGPR/PR		339	1.03	Int		Int
Aggressive NHL CR		181	1.05	Int		Int
Low-risk MDS adverse cytogenetics	Early†	103	1.06	High		Int
T-cell NHL PR		164	1.06	Int		Int
Low-risk MDS intermediate cytogenetics	Early†	516	1.09	Int		Int
HL PR		225	1.09	Int		Int
Low-risk MDS intermediate cytogenetics	Advanced†	235	1.18	Int		Int
Indolent NHL	Advanced†	128	1.21	Int		Int
CLL	Advanced	265	1.22	Int		Int
High-risk MDS intermediate cytogenetics	Early	364	1.24	Int		Int
Aggressive NHL PR		205	1.26	Int		Int
T-cell NHL	Advanced†	93	1.41	High	20	High	33	31-35
AML favorable cytogenetics	Advanced†	34	1.42	Int		High
HL	Advanced†	85	1.48	High		High
High-risk MDS intermediate cytogenetics	Advanced†	179	1.56	Int		High
High-risk MDS adverse cytogenetics	Early	80	1.58	High		High
ALL CR2		407	1.58	Int		High
AML adverse cytogenetics CR		175	1.59	High		High
Mantle cell lymphoma	Advanced†	46	1.59	High		High
High-risk MDS adverse cytogenetics	Advanced†	30	1.59	Very high		High
BL‡ CR		23	1.65	NA		High
Multiple myeloma	Advanced†	150	1.65	High		High
ALL CR3		61	1.70	Int		High
Low-risk MDS adverse cytogenetics	Advanced†	32	1.86	Very high		High
AML intermediate cytogenetics	Advanced	1227	1.89	High		High
CML blast phase		52	2.02	Int	4	Very high	23	20-27
ALL	Advanced†	235	2.23	High		Very high
Aggressive NHL	Advanced†	154	2.54	High		Very high
AML adverse cytogenetics	Advanced †	76	2.83	Very high		Very high
BL‡ PR	Advanced †	12	5.21	NA		Very high

Int, intermediate.

^*Hazard ratio for mortality compared with AML intermediate cytogenetics in CR1.

^†Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL, and CLL.

^‡Those categories were not included in the original DRI.